These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Genetic engineering patents. Contest in prospect over interferon rights. Beardsley T Nature; 1985 Mar 21-27; 314(6008):207. PubMed ID: 3982495 [No Abstract] [Full Text] [Related]
45. Medical-process patents. Klein RD N Engl J Med; 2007 Feb; 356(7):753-4. PubMed ID: 17301313 [No Abstract] [Full Text] [Related]
46. Pharmacogenomics: bench to bedside. Weinshilboum R; Wang L Nat Rev Drug Discov; 2004 Sep; 3(9):739-48. PubMed ID: 15340384 [TBL] [Abstract][Full Text] [Related]
47. The evolving role of natural products in drug discovery. Koehn FE; Carter GT Nat Rev Drug Discov; 2005 Mar; 4(3):206-20. PubMed ID: 15729362 [TBL] [Abstract][Full Text] [Related]
48. Pharmacogenomics: a new clinical or regulatory paradigm? European experiences of pharmacogenomics in drug regulation and regulatory initiatives. Prasad K; Breckenridge A Drug Discov Today; 2011 Oct; 16(19-20):867-72. PubMed ID: 21920454 [TBL] [Abstract][Full Text] [Related]
49. Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective. Lesko LJ; Woodcock J Nat Rev Drug Discov; 2004 Sep; 3(9):763-9. PubMed ID: 15340386 [TBL] [Abstract][Full Text] [Related]
50. Exclusivity strategies and opportunities in view of the Biologics Price Competition and Innovation Act. Gaudry KS Food Drug Law J; 2011; 66(4):587-630, ii. PubMed ID: 24505830 [TBL] [Abstract][Full Text] [Related]
51. Drug development and obstetrics: where are we right now? Thornton JG J Matern Fetal Neonatal Med; 2009; 22 Suppl 2():46-9. PubMed ID: 19951083 [No Abstract] [Full Text] [Related]
52. Test based on natural processes cannot be patented, rules US court. Dyer C BMJ; 2012 Mar; 344():e2290. PubMed ID: 22446741 [No Abstract] [Full Text] [Related]
53. SNPs--where's the beef? Roses AD Pharmacogenomics J; 2002; 2(5):277-83. PubMed ID: 12439733 [No Abstract] [Full Text] [Related]
54. Consent and privacy in pharmacogenetic testing. Robertson JA Nat Genet; 2001 Jul; 28(3):207-9. PubMed ID: 11431685 [TBL] [Abstract][Full Text] [Related]
55. Preparing for the revolution--pharmacogenomics and the clinical lab. Mehr IJ Pharmacogenomics; 2000 Feb; 1(1):1-4. PubMed ID: 11258591 [TBL] [Abstract][Full Text] [Related]
56. Antibacterial discovery and development--the failure of success? Fernandes P Nat Biotechnol; 2006 Dec; 24(12):1497-503. PubMed ID: 17160049 [TBL] [Abstract][Full Text] [Related]
57. How pharmacogenomics will impact the federal regulation of clinical trials and the new drug approval process. Binzak BA Food Drug Law J; 2003; 58(1):103-27. PubMed ID: 12739592 [No Abstract] [Full Text] [Related]
58. Pharmacogenomics: hope or hype? Coats AJ Int J Cardiol; 2000 Oct; 76(1):1-3. PubMed ID: 11121590 [No Abstract] [Full Text] [Related]
59. The myth of the biotech revolution. Nightingale P; Martin P Trends Biotechnol; 2004 Nov; 22(11):564-9. PubMed ID: 15491800 [TBL] [Abstract][Full Text] [Related]
60. The integration and interpretation of pharmacogenomics - a comparative study between the United States of America and Europe: towards better health care. Bartlett MJ; Shephard EA Drug Metab Pers Ther; 2016 Jun; 31(2):91-6. PubMed ID: 27269898 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]